Gout
Conditions
Interventions
SLFSN group:SLFSN group: SLFSN+QRQS simulated drug i.e. diclofenac sodium sustained-release tablets (trade name: Voltaren Beijing Novartis Pharmaceuticals Co. Ltd.) 1 tablet each time (75 mg) 1 time a
plus 1 dose of QRQS simulated drug (2L in total)/day taken frequently.
QRQS_K Medium dose group:QRQS_K medium-dose group: QRQS_K medium-dose + SLFSN simulation drug i.e. 1 dose (2L in total) of Qingrequshi formula granules (containing 50% Chinese medicine)/day taken fre
QRQS_K Low dose group:QRQS_K low-dose group: QRQS_K low-dose + SLFSN simulation drug i.e. 1 dose (2L in total) of Qingrequshi formula granules (containing 10% Chinese medicine)/day taken frequently pl
QRQS_K High dose group:QRQS_K high dose + SLFSN simulation drug i.e. 1 dose (2L in total) of Qingrequshi formula granules (containing 100% Chinese medicine)/day taken frequently plus 1 tablet (75mg) o
QRQS_T group:QRQS_T group: QRQS_T + SLFSN simulation drug i.e. 1 dose of traditional decoction for clearing away heat and removing dampness (2L in total)/day taken frequently plus 1 tablet of diclofen
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1)Meet the Western medical diagnosis criteria for gout; 2)3=VAS<7 points and the duration between gout attack and enrollment is =1 week; 3)Meet the TCM diagnosis criteria for damp-heat accumulation syndrome; 4)Age 18-70 years old; 5)Voluntarily participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Patients with secondary gout; 2) Oral contraceptives or hormone replacement therapy (prednisone dosage>10mg/d) within 3 months before the trial; 3) Patients with severe digestive tract diseases and digestive tract ulcers; 4) Patients with severe dysfunction of important organs such as heart brain liver and kidney and malignant tumors; 5) Patients with mental illness long-term alcohol abuse and drug abuse; 6) Pregnant or lactating patients; 7) Patients with allergic constitution or those who have been allergic to the components of this study's drugs; 8) Patients who are participating in other clinical trials that affect the evaluation of the results of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (visual analogue scaleVAS); | — |
Secondary
| Measure | Time frame |
|---|---|
| ESR;UA;CRP;TCM Syndrome Score; | — |
Countries
China
Contacts
Public ContactSunlu
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed